HK Stock Market Move | ZHIDA TECH (02650) rose nearly 6% to hit a new high since its listing. It has more than doubled from its IPO price. The company is a global leader in home charging stations.
ZhiDa Technology (02650) rose nearly 6% in the afternoon, reaching a high of 210.4 Hong Kong dollars, an increase of over 214% from the IPO price. As of the end of the report, it rose 5.03%, at 208.8 Hong Kong dollars, with a turnover of 111.057 million Hong Kong dollars.
ZHIDA TECH (02650) rose nearly 6% in the afternoon, reaching a high of 210.4 Hong Kong dollars, an increase of over 214% from the IPO price. As of the time of writing, it was up 5.03% at 208.8 Hong Kong dollars, with a turnover of 11.57 million Hong Kong dollars.
According to public information, as the world's largest provider of electric vehicle home charging solutions, ZHIDA TECH has deeply deployed a three-in-one model of "product + service + digital platform". According to Frost & Sullivan data, the company's global market share for home charging piles is approximately 9.0%, with a market share of 13.6% in China, ranking first in sales in the Chinese market.
It is worth noting that in November of this year, ZHIDA TECH once again amazed the market with cross-border innovation. Following the industry discussion sparked by its automatic charging Siasun Robot & Automation "spirit snake", ZHIDA TECH officially announced a strategic partnership with the super IP "Zhou Tongxue" from the Chinese music industry, jointly launching customized electric vehicle charging piles and themed charging stations, deeply integrating green travel with the trend culture of the Z generation.
Related Articles

Subsidiary YKYY018 of Youcare Pharmaceutical Group (688658.SH) receives FDA clinical trial approval for its nebulized inhalant.

Zhejiang Jiuzhou Pharmaceutical (603456.SH): The US FDA has approved the listing permit for the slow-release tablets of sitagliptin and metformin sustained release tablets.

Beijing Wandong Medical Technology (600055.SH) has received a medical device registration certificate.
Subsidiary YKYY018 of Youcare Pharmaceutical Group (688658.SH) receives FDA clinical trial approval for its nebulized inhalant.

Zhejiang Jiuzhou Pharmaceutical (603456.SH): The US FDA has approved the listing permit for the slow-release tablets of sitagliptin and metformin sustained release tablets.

Beijing Wandong Medical Technology (600055.SH) has received a medical device registration certificate.

RECOMMEND

Hong Kong Stock Buyback Wave Persists, 247 Listed Companies Repurchase Over HKD 150 Billion This Year
27/11/2025

Mingyu Pharmaceutical Files With HKEX: Ongoing Net Losses Since Inception, No Revenue From Commercial Product Sales
27/11/2025

“Affordability Crisis”! Consumer Confidence Falls To Second Lowest Since The Pandemic, U.S. Retail Slumps
27/11/2025


